Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Mario Cazzola, Nicola A Hanania, Clive P Page & Maria Gabriella Matera. (2023) Novel Anti-Inflammatory Approaches to COPD. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 1333-1352.
Read now
Read now
Luigino Calzetta, Elena Pistocchini, Alfredo Chetta, Paola Rogliani & Mario Cazzola. (2023) Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval. Expert Opinion on Investigational Drugs 32:6, pages 525-536.
Read now
Read now
Maria Gabriella Matera, Josuel Ora, Francesco Cavalli, Paola Rogliani & Mario Cazzola. (2021) New Avenues for Phosphodiesterase Inhibitors in Asthma. Journal of Experimental Pharmacology 13, pages 291-302.
Read now
Read now
Timothy E. Albertson, James A. Chenoweth, Skyler J. Pearson & Susan Murin. (2020) The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS). Expert Opinion on Pharmacotherapy 21:2, pages 213-231.
Read now
Read now
Mario Cazzola, Luigino Calzetta, Paola Rogliani & Maria Gabriella Matera. (2019) Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of
COPD. Expert Opinion on Investigational Drugs 28:10, pages 827-833.
Read now
Read now
Paola Rogliani, Vito Brusasco, Leonardo Fabbri, Andrea Ungar, Elisa Muscianisi, Ilaria Barisone, Alberto Corsini & Giuseppe De Angelis. (2018) Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 12:2, pages 103-112.
Read now
Read now
Articles from other publishers (31)
Toby M Maher, Shervin Assassi, Arata Azuma, Vincent Cottin, Anna-Maria Hoffmann-Vold, Michael Kreuter, Justin M Oldham, Luca Richeldi, Claudia Valenzuela, Marlies S Wijsenbeek, Carl Coeck, Christina Schlecker, Florian Voss, Daniel Wachtlin & Fernando J Martinez. (2023) Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD). BMJ Open Respiratory Research 10:1, pages e001580.
Crossref
Crossref
Luca Richeldi, Arata Azuma, Vincent Cottin, Michael Kreuter, Toby M Maher, Fernando J Martinez, Justin M Oldham, Claudia Valenzuela, Maud Gordat, Yi Liu, Susanne Stowasser, Donald F Zoz & Marlies S Wijsenbeek. (2023) Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF). BMJ Open Respiratory Research 10:1, pages e001563.
Crossref
Crossref
Katarzyna Wójcik-Pszczoła, Krzysztof Pociecha, Grażyna Chłoń-Rzepa, Monika Zadrożna, Barbara Nowak, Hanna Plutecka, Paulina Koczurkiewicz-Adamczyk, Katarzyna Przejczowska-Pomierny, Elżbieta Pękala, Reinoud Gosens & Elżbieta Wyska. (2023) Inhaled pan-phosphodiesterase inhibitors ameliorate ovalbumin-induced airway inflammation and remodeling in murine model of allergic asthma. International Immunopharmacology 119, pages 110264.
Crossref
Crossref
Martin Kolb, Bruno Crestani & Toby M. Maher. (2023) Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. European Respiratory Review 32:167, pages 220206.
Crossref
Crossref
Gang Li, Dengqin He, Xiaojia Cai, Wen Guan, Yali Zhang, Jia-Qiang Wu & Hongliang Yao. (2023) Advances in the development of phosphodiesterase-4 inhibitors. European Journal of Medicinal Chemistry 250, pages 115195.
Crossref
Crossref
Ping Mao, Changhao Huang, Yuyu Li, Yuanyi Zhao, Sujin Zhou, Zhenggang Zhao, Yunping Mu, Lina Wang, Fanghong Li & Allan Z. Zhao. (2023) Pharmacological targeting of type phosphodiesterase 4 inhibits the development of acute myeloid leukemia by impairing mitochondrial function through the Wnt/β-catenin pathway. Biomedicine & Pharmacotherapy 157, pages 114027.
Crossref
Crossref
Toby M. Maher, Christina Schlecker, Doreen Luedtke, Sebastian Bossert, Donald F. Zoz & Armin Schultz. (2022) Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis. ERJ Open Research 8:4, pages 00240-2022.
Crossref
Crossref
Luca RicheldiArata AzumaVincent Cottin, Christian HesslingerSusanne StowasserClaudia ValenzuelaMarlies S. Wijsenbeek, Donald F. ZozFlorian VossToby M. Maher. (2022) Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. New England Journal of Medicine 386:23, pages 2178-2187.
Crossref
Crossref
Dennis Williams. (2020) The Role of the Pharmacist in Optimizing Outcomes With Roflumilast, a PDE4 Inhibitor for the Treatment of COPD. Journal of Pharmacy Practice 35:3, pages 445-454.
Crossref
Crossref
Sherri Dudal, Caterina Bissantz, Antonello Caruso, Pascale David-Pierson, Wouter Driessen, Erich Koller, Ben-Fillippo Krippendorff, Martin Lechmann, Andrés Olivares-Morales, Axel Paehler, Caroline Rynn, Dietrich Türck, Arthur Van De Vyver, Ken Wang & Lotte Winther. (2022) Translating pharmacology models effectively to predict therapeutic benefit. Drug Discovery Today 27:6, pages 1604-1621.
Crossref
Crossref
Mario Cazzola, Josuel Ora, Luigino Calzetta, Paola Rogliani & Maria Gabriella Matera. (2022) The future of inhalation therapy in chronic obstructive pulmonary disease. Current Research in Pharmacology and Drug Discovery 3, pages 100092.
Crossref
Crossref
Tonio Pera, Cali Loblundo & Raymond B. Penn. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
762
802
.
Bruno Sposato, Elisa Petrucci, Andrea Serafini, Fabio Lena, Leonardo Gianluca Lacerenza, Andrea Montagnani, Massimo Alessandri, Alberto Cresti, Raffaele Scala, Paola Rogliani, Alberto Ricci, Antonio Perrella & Marco Scalese. (2021) Which LABA/LAMA should be chosen in COPD patients in real life?. Pulmonary Pharmacology & Therapeutics 71, pages 102076.
Crossref
Crossref
Teresa Wegesser, Aldo Coppi, Tod HarperJr.Jr., Maria Paris & Sheroy Minocherhomji. (2021) Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4. Regulatory Toxicology and Pharmacology 125, pages 104985.
Crossref
Crossref
Ingrid Allart-Simon, Aurélie Moniot, Nicolo Bisi, Miguel Ponce-Vargas, Sandra Audonnet, Marie Laronze-Cochard, Janos Sapi, Eric Hénon, Frédéric Velard & Stéphane Gérard. (2021) Pyridazinone derivatives as potential anti-inflammatory agents: synthesis and biological evaluation as PDE4 inhibitors. RSC Medicinal Chemistry 12:4, pages 584-592.
Crossref
Crossref
Tadashi Honda & Iwao Ojima. 2021. The Curious World of Fluorinated Molecules. The Curious World of Fluorinated Molecules
241
276
.
Shvetank Bhatt, Jovita Kanoujia, A. N. Nagappa & K. Sreedhara R. Pai. 2021. Targeting Cellular Signalling Pathways in Lung Diseases. Targeting Cellular Signalling Pathways in Lung Diseases
127
146
.
Shradha Bodkhe, Mayuri Nikam, Atul P. Sherje, Tabassum Khan, Vasanti Suvarna & Kavit Patel. (2020) Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS. International Immunopharmacology 88, pages 106906.
Crossref
Crossref
Jonathan E. Phillips. (2020) Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases. Frontiers in Pharmacology 11.
Crossref
Crossref
Mario Cazzola, Paola Rogliani, Daiana Stolz & Maria Gabriella Matera. (2019) Pharmacological treatment and current controversies in COPD. F1000Research 8, pages 1533.
Crossref
Crossref
Li Xing, Tadashi Honda, Lori Fitz & Iwao Ojima. 2019. Fluorine in Life Sciences: Pharmaceuticals, Medicinal Diagnostics, and Agrochemicals. Fluorine in Life Sciences: Pharmaceuticals, Medicinal Diagnostics, and Agrochemicals
181
211
.
Heng Li, Jianping Zuo & Wei Tang. (2018) Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Frontiers in Pharmacology 9.
Crossref
Crossref
Jan Seibel, Kirill Kryshen, Judit E. Pongrácz & Martin D. Lehner. (2018) In vivo and in vitro investigation of anti-inflammatory and mucus-regulatory activities of a fixed combination of thyme and primula extracts. Pulmonary Pharmacology & Therapeutics 51, pages 10-17.
Crossref
Crossref
Paola Rogliani, Josuel Ora, Ermanno Puxeddu, Luigino Calzetta, Francesco Cavalli, Maria Gabriella Matera & Mario Cazzola. (2018) Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. Pulmonary Pharmacology & Therapeutics 49, pages 20-26.
Crossref
Crossref
Hui Yu, Zhengqiang Zou, Xiaolin Zhang, Wanli Peng, Chen Chen, Yicheng Ye, Jiangping Xu & Haitao Wang. (2018) Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice: Involvement of p38 and JNK Signaling Pathways. International Journal of Molecular Sciences 19:2, pages 513.
Crossref
Crossref
Chantal Barberot, Aurélie Moniot, Ingrid Allart-Simon, Laurette Malleret, Tatiana Yegorova, Marie Laronze-Cochard, Abderrazzaq Bentaher, Maurice Médebielle, Jean-Philippe Bouillon, Eric Hénon, Janos Sapi, Frédéric Velard & Stéphane Gérard. (2018) Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents. European Journal of Medicinal Chemistry 146, pages 139-146.
Crossref
Crossref
L. Calzetta, P. Roncada, D. di Cave, L. Bonizzi, A. Urbani, E. Pistocchini, P. Rogliani & M. G. Matera. (2017) Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis. Equine Veterinary Journal 49:6, pages 710-717.
Crossref
Crossref
Brijeshkumar S. Patel, Md. Mostafizur Rahman, Gina Baehring, Dikaia Xenaki, Francesca Su-May Tang, Brian G. Oliver & Alaina J. Ammit. (2017)
Roflumilast
N
-Oxide in Combination with Formoterol Enhances the Antiinflammatory Effect of Dexamethasone in Airway Smooth Muscle Cells
. American Journal of Respiratory Cell and Molecular Biology 56:4, pages 532-538.
Crossref
Crossref
Luigino Calzetta, Paola Rogliani, Josuel Ora, Ermanno Puxeddu, Mario Cazzola & Maria Gabriella Matera. (2017) LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. European Respiratory Review 26:143, pages 160043.
Crossref
Crossref
Mario Cazzola, Luigino Calzetta, Paola Rogliani & Maria Gabriella Matera. (2016) Tiotropium formulations and safety: a network meta-analysis. Therapeutic Advances in Drug Safety 8:1, pages 17-30.
Crossref
Crossref
D. Spina & C. P. Page. 2017. Pharmacology and Therapeutics of Asthma and COPD. Pharmacology and Therapeutics of Asthma and COPD
63
91
.